title: Bilateral lesions of the entorhinal cortex differentially modify haloperidol- and olanzapine-induced c-fos mRNA expression in the rat forebrain.
abstract: Lesions of the entorhinal cortex are now an accepted model for mimicking some of the neuropathological aspects of schizophrenia, since evidence has accumulated for the presence of cytoarchitectonic abnormalities within this cortex in schizophrenic patients. The present study was undertaken to address the functional consequences of bilateral entorhinal cortex lesions on antipsychotic-induced c-fos expression. After a 15-day recovery period, the effect of a typical antipsychotic, haloperidol (1 mg/kg), on c-fos mRNA expression was compared with that of an atypical one, olanzapine (10 mg/kg), in both sham-lesioned and entorhinal cortex-lesioned rats. In sham-lesioned rats, both haloperidol and olanzapine induced c-fos expression in the caudal cingulate cortex, dorsomedial and dorsolateral caudate-putamen, nucleus accumbens core and shell and lateral septum. In addition, olanzapine, but not haloperidol, increased c-fos expression within the central amygdala. In entorhinal cortex-lesioned rats, haloperidol-induced c-fos expression was markedly reduced in most areas. In contrast, the olanzapine-induced c-fos expression was not altered in the nucleus accumbens shell and lateral septum of the lesioned rats. These findings reveal that entorhinal cortex lesions affect c-fos expression in a compound- and regional-dependent manner. Our results further emphasize the importance of the exploration of the mechanisms of action of antipsychotic drugs in the context of an associated cortical pathology.
authors.affiliation: Laboratoire de Neurosciences Comportementales et Cognitives, UMR 7521, Université Louis Pasteur, CNRS, IFR des Neurosciences, Strasbourg, France. alexandre.seillier@psycho-ulp.u-strasbg.fr
authors.forename: A
authors.initials: A
authors.lastname: Seillier
authors.forename: E
authors.initials: E
authors.lastname: Coutureau
authors.forename: N
authors.initials: N
authors.lastname: Thiriet
authors.forename: K
authors.initials: K
authors.lastname: Herbeaux
authors.forename: J
authors.initials: J
authors.lastname: Zwiller
authors.forename: G
authors.initials: G
authors.lastname: Di Scala
authors.forename: B
authors.initials: B
authors.lastname: Will
authors.forename: M
authors.initials: M
authors.lastname: Majchrzak
mesh_terms: D000818:Animals; D001569:Benzodiazepines; D018728:Entorhinal Cortex / Q000187:drug effects* / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D016762:Genes, fos / Q000187:drug effects* / Q000502:physiology; D006220:Haloperidol / Q000494:pharmacology*; D008297:Male; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D016548:Prosencephalon / Q000187:drug effects* / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D020318:Rats, Long-Evans
chemical_list: D012333:RNA, Messenger; D001569:Benzodiazepines; D010890:Pirenzepine; D006220:Haloperidol; D000077152:Olanzapine